
    
      The drug being tested in this study is called TAK-272. This study evaluated the dose-response
      relationship of the efficacy and safety of TAK-272 in participants with type 2 diabetes
      mellitus and microalbuminuria.

      The study enrolled 415 patients. Participants were randomly assigned to one of the 6
      treatment groups:

        -  TAK-272 5 mg

        -  TAK-272 20 mg

        -  TAK-272 40 mg

        -  TAK-272 80 mg

        -  Candesartan cilexetil 8 mg

        -  Placebo (dummy inactive pill) for TAK-272 or Candesartan cilexetil - this was a tablet
           that looks like the study drug but had no active ingredient

      All participants were administered tablets, orally at the same time each day for 12 weeks in
      double-blind manner. Participants were administered TAK-272 placebo 4 tablets and Candesartan
      cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and
      follow-up period (Week 12-14).

      This multi-center trial was conducted in Japan. The overall time to participate in this study
      is 22 weeks including 2 weeks of follow-up assessment period after last dose of study drug.
      Participants made multiple visits to the clinic during these periods.
    
  